ZYN Pouches Seek FDA Nod as Lower-Risk Tobacco Alternative
Published Date: 6/18/2025
Notice
Summary
Swedish Match U.S.A., Inc. wants the FDA to approve their ZYN nicotine pouches as lower-risk tobacco products. This means people could see new labels saying these pouches might be safer than regular tobacco. The FDA is asking the public to share their thoughts before making a decision, so your voice matters!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
ZYN Pouches 'Lower-Risk' Labeling
Swedish Match submitted modified risk tobacco product applications asking the FDA to allow ZYN nicotine pouches to be marketed as lower-risk. If the FDA approves, people could see new labels or claims saying these pouches might be safer than regular tobacco.
FDA Opens Public Comment Opportunity
The FDA is asking the public to submit comments on the modified risk tobacco product applications for ZYN nicotine pouches. You can share your views with the FDA before it decides whether to allow labels claiming these pouches are lower-risk.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16536, Kremers Urban Pharmaceuticals, Inc.; Grant of Hearing Request Regarding a Proposal To Withdraw Approval of an Abbreviated New Drug Application for Extended-Release Methylphenidate Tablets
The Food and Drug Administration (FDA or the Agency) is announcing a formal evidentiary public hearing on the proposal to withdraw approval of the abbreviated new drug application (ANDA) 091695, submitted by Kremers Urban Pharmaceuticals, Inc. (Kremers) for methylphenidate hydrochloride extended-release tablets. On October 18, 2016, the Director of FDA's Center for Drug Evaluation and Research (CDER) published a notice of opportunity for hearing on a proposal to withdraw approval of ANDA 091695. Kremers submitted a timely request for hearing on that proposal. This notice of hearing provides factual and legal information concerning CDER's proposal to withdraw approval of ANDA 091695 and identifies the factual issues that will be the subject of the evidentiary hearing.
2026-16452, Formal Meetings Between the Food and Drug Administration and Sponsors or Applicants of Prescription Drug User Fee Act Products; Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products." This guidance outlines the recommendations to industry on formal meetings between FDA and sponsors or applicants relating to the development and review of new drug or biological products regulated by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER). This guidance finalizes the draft guidance of the same title issued on September 22, 2023.
2026-16420, Guide To Minimize Biological Hazards in Ready-to-Eat Fresh-Cut Produce; Guidance for Industry; Availability
The Food and Drug Administration (FDA or we) is announcing the availability of a final guidance for industry entitled "Guide to Minimize Biological Hazards in Ready-to-Eat Fresh-Cut Produce." This guidance supersedes a previous guidance, entitled "Guide to Minimize Microbial Food Safety Hazards of Fresh-Cut Fruits and Vegetables," issued in 2008, and is a final guidance to the draft guidance for industry entitled "Guide to Minimize Food Safety Hazards of Fresh-Cut Produce" issued in 2018. The guidance is intended to help manufacturers or processors of ready-to-eat fresh-cut produce that is not a low-moisture food comply with applicable requirements in our regulations on current good manufacturing practices for hazard analysis and risk-based preventive controls for human food.
Previous / Next Documents
Previous: 2025-11170, NTIA Listening Session on Bolstering Data Center Growth, Resilience and Security
The NTIA is hosting a virtual chat to hear ideas on making data centers stronger, safer, and ready for the future. This is for companies and communities that rely on data centers to keep things running smoothly. The feedback will help shape new plans and policies soon, aiming to boost growth and security without delay.
Next: 2025-10985, Privacy Act of 1974; Matching Program
The Department of Health and Human Services is restarting a program that matches state TANF records with new job and wage info to make sure only the right people get benefits. This helps catch errors and keep the program honest. If you’re involved with TANF, expect smoother checks soon, with no extra costs announced.